PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Annals Of Oncology : Official Journal Of The European Society For Medical Oncology
Loibl, S S; Majewski, I I; Guarneri, V V; Nekljudova, V V; Holmes, E E; Bria, E E; Denkert, C C; Schem, C C; Sotiriou, C C; Loi, S S; Untch, M M; Conte, P P; Bernards, R R; Piccart, M M; von Minckwitz, G G; Baselga, J J